Sotalol 40mg tablets

Nchi: Uingereza

Lugha: Kiingereza

Chanzo: MHRA (Medicines & Healthcare Products Regulatory Agency)

Viambatanisho vya kazi:

Sotalol hydrochloride

Inapatikana kutoka:

Teva UK Ltd

ATC kanuni:

C07AA07

INN (Jina la Kimataifa):

Sotalol hydrochloride

Kipimo:

40mg

Dawa fomu:

Oral tablet

Njia ya uendeshaji:

Oral

Darasa:

No Controlled Drug Status

Dawa ya aina:

Valid as a prescribable product

Bidhaa muhtasari:

BNF: 02040000; GTIN: 5017007012375

Taarifa za kipeperushi

READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR
YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have further questions, please ask your doctor or your
pharmacist.
•
This medicine has been prescribed for you only. Do not pass
it on to others. It may harm them, even if their signs of illness
are the same as yours.
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects not listed in this leaflet. See
Section 4.
IN THIS LEAFLET:
1.
What Sotalol Tablets are and what they are used for
2.
What you need to know before you take Sotalol Tablets
3.
How to take Sotalol Tablets
4.
Possible side effects
5.
How to store Sotalol Tablets
6.
Contents of the pack and further information
1. WHAT SOTALOL TABLETS ARE AND WHAT THEY ARE USED FOR
Sotalol Tablets contain the active ingredient Sotalol. Sotalol belongs
to a group of drugs called beta-adrenergic blocking agents or
“beta-blockers.” Sotalol is used to treat irregular heartbeats.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE SOTALOL TABLETS
Do not take Sotalol Tablets:
•
if you are ALLERGIC to sotalol hydrochloride or any of the other
ingredients in this medicine (listed in section 6).
•
if you suffer from ASTHMA, attacks of wheezing or any other
lung disease.
•
if you have a very slow heart beat or LOW BLOOD PRESSURE.
•
if you suffer from a condition causing discolouration (white or
purple) of the hands and feet (Raynaud’s syndrome).
•
if you suffer from any severe CIRCULATION DISORDERS.
•
if you have suffered from HEART DISEASE (such as untreated
heart failure) or had a recent heart attack that your doctor does
not know about.
•
if you suffer from a condition called METABOLIC ACIDOSIS.
•
if you suffer from an untreated tumour of the adrenal gland
•
if you suffer from KIDNEY FAILURE
If you are affected by any of the above you should tell your doctor
before taking this medicine.
WARNINGS AND PRECAUTIONS
Talk to your d

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Sotalol 40mg Tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 40mg Sotalol hydrochloride
For excipients: see 6.1
3.
PHARMACEUTICAL FORM
Tablet
Round, white to off-white, flat bevelled edged tablets.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
Sotalol 40mg Tablets are indicated for:
_1. _
_VENTRICULAR ARRHYTHMIAS: _
•
Treatment of life-threatening ventricular tachyarrhythmias;
•
Treatment of symptomatic non-sustained ventricular tachyarrhythmias
_2. _
_SUPRAVENTRICULAR ARRHYTHMIAS: _
•
Prophylaxis of paroxysmal atrial tachycardia, paroxysmal atrial
fibrillation, paroxysmal A-V nodal re-entrant tachycardia, paroxysmal
A-V
re-entrant tachycardia using accessory pathways, and paroxysmal
supraventricular tachycardia after cardiac surgery;
•
Maintenance of normal sinus rhythm following conversion of atrial
fibrillation or atrial flutter
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
As with other antiarrhythmic agents, it is recommended that Sotalol
40mg Tablets be
initiated and doses increased in a facility capable of monitoring and
assessing cardiac
rhythm. The dosage must be individualized and based on the patient's
response.
Proarrhythmic events can occur not only at initiation of therapy, but
also with each
upward dosage adjustment.
In view of its
β
-adrenergic blocking properties, treatment with Sotalol 40mg Tablets
should not be discontinued suddenly, especially in patients with
ischaemic heart
disease (angina pectoris, prior acute myocardial infarction) or
hypertension, to
prevent exacerbation of the disease (see 4.4 Warnings).
The initiation of treatment or changes in dosage with sotalol should
follow an
appropriate medical evaluation including ECG control with measurement
of the
corrected QT interval, and assessment of renal function, electrolyte
balance and
concomitant medications (See 4.4 Warnings and precautions).
Method of administration
The following dosing schedule can be recommended:
The ini